✦ LIBER ✦

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

✍ Scribed by Picard, S.; Titier, K.; Etienne, G.; Teilhet, E.; Ducint, D.; Bernard, M.-A.; Lassalle, R.; Marit, G.; Reiffers, J.; Begaud, B.; Moore, N.; Molimard, M.; Mahon, F.-X.

Book ID: 121684340
Publisher: American Society of Hematology
Year: 2006
Tongue: English
Weight: 81 KB
Volume: 109
Category: Article
ISSN: 0006-4971
DOI: 10.1182/blood-2006-07-036012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cytogenetic and molecular responses to s

Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels

✍ Donna L. Forrest; Shannon Trainor; Ryan R. Brinkman; Michael J. Barnett; Donna E 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Trough plasma imatinib levels are correl

Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia

✍ Sohn, Sang Kyun; Oh, Suk Joong; Kim, Byung Soo; Ryoo, Hun Mo; Chung, Joo Seop; J 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 250 KB

Cytogenetic and molecular responses in c

Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose

✍ Massimo Breccia; Laura Cannella; Caterina Stefanizzi; Roberto Latagliata; Mauro 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

## Abstract Imatinib mesylate is the gold standard treatment of chronic myeloid leukaemia (CML) and 400 mg/day is considered the standard dose. Although it is generally well tolerated, some patients require temporary drug discontinuation and permanent dose reduction because of haematological or non

ABCB1 haplotype is associated with major

ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib

✍ Douglas Vivona; Carolina T. Bueno; Luciene T. Lima; Rosario D.C. Hirata; Mario H 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 251 KB

Delayed cytogenetic and major molecular

Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib

✍ Breccia, Massimo; Loglisci, Giuseppina; Salaroli, Adriano; Serrao, Alessandra; M 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 150 KB

Imatinib trough plasma levels do not cor

Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting

✍ Edgar Faber; David Friedecký; Kateřina Mičová; Šárka Rožmanová; Martina Divoká; 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 227 KB